USP47: A Potential Drug Target and Biomarker for Ubiquitin-Specific Processing Protease 47

Target Name: USP47

NCBI ID: G55031

USP47

USP47: A Potential Drug Target and Biomarker for Ubiquitin-Specific Processing Protease 47

Ubiquitin (Upp) is a protein that plays a crucial role in the regulation of protein-protein interactions, DNA replication, and apoptosis. It is a small protein that consists of 21 amino acids and is highly conserved across various species. Ubiquitin is covalently bound to a variety of protein targets, including other proteins known as ubiquitin-proteasomes (UPs) and ubiquitin-activating enzymes (UAPs).

The ubiquitin-specific processing protease 47 (USP47) is a protein that is expressed in various cell types and is involved in the processing of Ubiquitin. USP47 is a 23 kDa protein that contains a unique N-terminal region that is specific to Ubiquitin. It plays a critical role in the regulation of protein degradation and is also a potential drug target.

In this article, we will discuss USP47, its function in the context of Ubiquitin-specific processing, its potential as a drug target, and its potential as a biomarker.

Function of USP47

USP47 is a member of the superfamily of ubiquitin-proteasome enzymes (UPEs) and is responsible for the processing of Ubiquitin. It is a highly conserved protein that contains a unique N-terminal region that is specific to Ubiquitin. This unique N-terminal region is known as the N-terminal domain and is responsible for the formation of a covalent complex with the protein ubiquitin.

The N-terminal domain of USP47 is involved in the formation of a covalent complex with Ubiquitin through a unique mechanism. The N-terminal domain of USP47 contains a farnesylated cysteine residue, which is known as a cysteine-3-fold loop (C3L). This C3L plays a critical role in the formation of the covalent complex between USP47 and Ubiquitin.

The processing of Ubiquitin by USP47 is critical for the regulation of protein degradation. Ubiquitin is involved in the regulation of protein stability, localization, and interactions with other proteins. The processing of Ubiquitin by USP47 allows it to be targeted for degradation and removal from the cell.

Potential Drug Target

USP47 is a potential drug target due to its involvement in the regulation of protein degradation. Drugs that target USP47 have the potential to treat a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

One of the potential benefits of targeting USP47 is its potential to treat cancer. Cancer cells often have increased levels of Ubiquitin and are dependent on the processing of Ubiquitin by USP47 for their survival. Targeting USP47 with drugs that inhibit its activity could be a promising strategy for cancer treatment.

Another potential drug target for USP47 is its role in the regulation of neurodegenerative diseases. The processing of Ubiquitin by USP47 is involved in the regulation of protein degradation, which is a critical process for the maintenance of normal brain function. Abnormalities in protein degradation have been implicated in a variety of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Targeting USP47 with drugs that enhance its activity could be a promising strategy for the treatment of these diseases.

Potential Biomarker

USP47 is also a potential biomarker for a variety of diseases. The processing of Ubiquitin by USP47 is involved in the regulation of protein degradation, which is a critical process for the maintenance of normal

Protein Name: Ubiquitin Specific Peptidase 47

Functions: Ubiquitin-specific protease that specifically deubiquitinates monoubiquitinated DNA polymerase beta (POLB), stabilizing POLB thereby playing a role in base-excision repair (BER). Acts as a regulator of cell growth and genome integrity. May also indirectly regulate CDC25A expression at a transcriptional level

The "USP47 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about USP47 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets